Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its...
Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its Lymphoseek cancer-detection drug was rejected. However, shares are up 5.8% AH after a spokesperson says Neoprobe isn't aware of any news about its application, which the FDA is expected to decide upon by Oct. 24.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs